Krystal Biotech Inc. (KRYS)
Krystal Biotech: Vyjuvek Is Not The Primary Asset
Krystal Biotech leverages its HSV-1 gene delivery platform, with VYJUVEK generating strong cash flow and 95% gross margins since FDA approval. KRYS is rated Buy, justified by a robust pipeline—especially oncology flagship KB707—and a $1B cash position supporting R&D without dilution risk. VYJUVEK's international rollout and pipeline catalysts could drive annual net income to $1.8–$2.9B, with forward PE potentially as low as 2.9–4.6.
Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus
KRYS shares jump after a Q1 beat as Vyjuvek fuels 32% revenue growth, strong uptake and global expansion, with pipeline catalysts lined up through 2026.
Krystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call Transcript
Krystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call Transcript
Krystal Biotech, Inc. (KRYS) Tops Q1 Earnings and Revenue Estimates
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.83 per share, beating the Zacks Consensus Estimate of $1.45 per share. This compares to earnings of $1.2 per share a year ago.
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Krystal Biotech (KRYS) Down 11.5% Since Last Earnings Report?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark
KRYS beats Q4 estimates as Vyjuvek sales jump 17%. It secures 660+ U.S. reimbursements and advances the gene therapy pipeline into 2026.
Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript
Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript
Krystal: Profitable Growth And The Expanding Reach Of HSV-1 Technology
Krystal Biotech remains a "Buy" as VYJUVEK's strong launch powers profitability, and pipeline catalysts offer further upside. Krystal Biotech's valuation is underpinned by VYJUVEK's blockbuster trajectory, high gross margins (94%), and disciplined R&D and SG&A spending. Phase 1 KB407 data in cystic fibrosis confirms molecular proof-of-concept, with a $2B+ opportunity targeting modulator-ineligible and suboptimal responder patients.
Krystal Biotech: KB707 Program Bolstered By RMAT And 2nd Half 2026 Update
Krystal Biotech maintains a 'Strong Buy' rating, driven by robust VYJUVEK sales and significant pipeline progress. Krystal Biotech received FDA RMAT designation for inhaled KB707 in advanced NSCLC, based on a 36% ORR in heavily pretreated patients. A single registrational trial of KB707 plus chemotherapy versus chemotherapy alone may support regulatory filing, with interim analysis expected in H2 2026.
Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable
Krystal Biotech (KRYS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Are You Looking for a Top Momentum Pick? Why Krystal Biotech, Inc. (KRYS) is a Great Choice
Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
